Evidence map›Paper›PMID 41053667›Full record

SynthesisBMC ophthalmology2025

A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis.

Mohammad Shojaeinia, Azamossadat Hosseini, Mostafa Naderi, Bardia Baloutch, Mohammad Shokoohi Yekta, Leila Akbarpour, Hamid Moghaddasi

Abstract readSystematic Review
In one paragraph

Synthesis in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad ShojaeiniaDepartment of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Darband Street, Tehran, 1971653313, Iran.
Azamossadat HosseiniDepartment of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Darband Street, Tehran, 1971653313, Iran.
Mostafa NaderiDepartment of Ophthalmology, Bina Eye Hospital, Tehran, Iran.
Bardia BaloutchTRUST/FALCON RAY Imaging (X-Ray and Visible Spectrum), Tehran, Iran.
Mohammad Shokoohi YektaHead of AI, Bioxytech Retina Inc, Richmond, CA, USA.
Leila AkbarpourDepartment of Foreign Languages, Shiraz Branch, Islamic Azad University, Shiraz, Fars, Iran.
Hamid MoghaddasiDepartment of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Darband Street, Tehran, 1971653313, Iran. moghaddasi@sbmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo synthesize evidence on deep learning applications for diagnosing central serous chorioretinopathy (CSCR), a macular disorder associated with vision loss, this systematic review categorized studies by diagnostic task and imaging modality. The study evaluates advances in deep learning performance, clinical integration potential, dataset limitations, and the contributions of multimodal imaging and Explainable AI (XAI) to diagnostic accuracy and clinical decision-making.

methodsWe conducted a PRISMA-compliant systematic review of PubMed, Scopus, and IEEE Xplore, including peer-reviewed English-language studies published from January 1990 to February 2024 that reported quantitative deep learning metrics for CSCR diagnosis. A two-stage selection process was applied (Cohen's κ = 0.84), resulting in 96 studies for analysis. Risk of bias was evaluated using the QUADAS-2 tool, and data were synthesized by imaging modality, model architecture, and diagnostic task.

resultsDeep learning models demonstrate exceptional performance in CSCR diagnosis. DenseNet architectures applied to optical coherence tomography (OCT) images achieved peak Metrics, including 99.78% accuracy, 99.68% sensitivity, and 100% specificity. Segmentation models for subretinal fluid (SRF) reported Dice scores of up to 0.965, while multimodal models for differential diagnosis achieved an area under the curve (AUC) of 0.999. Despite these advances, clinical adoption remains limited by several challenges: scarce and imbalanced datasets (e.g., SRF/non-SRF ratio of 1:8), lack of open-access datasets and models, risks of overfitting, and insufficient external validation. Emerging approaches, such as few-shot learning and diffusion models, are promising for mitigating data constraints; however, improvements in dataset quality and the implementation of rigorous cross-institutional validation are essential for real-world deployment.

conclusionsBy leveraging OCT and multimodal imaging data, deep learning has the potential to transform CSCR diagnosis through enhanced accuracy and automation. However, translating these advances into routine clinical practice necessitates overcoming key challenges, including limited and heterogeneous datasets and models with restricted generalizability. Future research should prioritize standardized reporting frameworks, transparent model interpretability through XAI, and rigorous large-scale validation. Essential strategies include employing federated learning to leverage distributed data, implementing effective multimodal fusion techniques, and fostering collaborative frameworks to improve diagnostic accuracy, ensure algorithmic fairness, and enable real-world clinical applicability.

Indexed as

Central Serous ChorioretinopathyDeep LearningHumansTomography, Optical CoherenceArtificial intelligenceCentral serous chorioretinopathyDeep learningDiagnosisMachine learningRetinopathy

Identifiers

PMID41053667
PMCPMC12502260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.